 |
PDBsum entry 3fje
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
393:128-139
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis of conserved cysteine in the fibroblast growth factor family: evidence for a vestigial half-cystine.
|
|
J.Lee,
M.Blaber.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The 22 members of the mouse/human fibroblast growth factor (FGF) family of
proteins contain a conserved cysteine residue at position 83 (numbering scheme
of the 140-residue form of FGF-1). Sequence and structure information suggests
that this position is a free cysteine in 16 members and participates as a
half-cystine in at least 3 (and perhaps as many as 6) other members. While a
structural role as a half-cystine provides a stability basis for possible
selective pressure, it is less clear why this residue is conserved as a free
cysteine (although free buried thiols can limit protein functional half-life).
To probe the structural role of the free cysteine at position 83 in FGF-1, we
constructed Ala, Ser, Thr, Val, and Ile mutations and determined their effects
on structure and stability. These results show that position 83 in FGF-1 is
thermodynamically optimized to accept a free cysteine. A second cysteine
mutation was introduced into wild-type FGF-1 at adjacent position Ala66, which
is known to participate as a half-cystine with position 83 in FGF-8, FGF-19, and
FGF-23. Results show that, unlike position 83, a free cysteine at position 66
destabilizes FGF-1; however, upon oxidation, a near-optimal disulfide bond is
formed between Cys66 and Cys83, resulting in approximately 14 kJ/mol of
increased thermostability. Thus, while the conserved free cysteine at position
83 in the majority of the FGF proteins may have a principal role in limiting
functional half-life, evidence suggests that it is a vestigial half-cystine.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Fig. 2. Relaxed stereo diagram of the X-ray crystal
structures (molecule A in the asymmetric unit in each case) of
position 83 mutants of FGF-1 (CPK coloring) showing the
structural details adjacent to the site of mutation and overlaid
with the coordinates of wild-type FGF-1 (PDB code 1JQZ; light
gray). (a) Cys83 → Ala. (b) Cys83 → Ser. (c) Cys83 → Thr.
(d) Cys83 → Val. (e) Cys83 → Ile.
|
 |
Figure 3.
Fig. 3. Relaxed stereo diagram of the X-ray crystal
structures of the reduced and oxidized forms of the Ala66 →
Cys mutant (CPK coloring). (a) Molecule A in the asymmetric unit
of reduced Ala66 → Cys overlaid with wild-type FGF-1 (PDB code
1JQZ; light gray). (b) Molecule B in the asymmetric unit of
reduced Ala66 → Cys overlaid with wild-type FGF-1 (PDB code
1JQZ; light gray). (c) Molecule A of oxidized Ala66 → Cys
overlaid with wild-type FGF-1 (PDB code 1JQZ; light gray). (d)
Molecule A of oxidized Ala66 → Cys overlaid with FGF-23 (PDB
code 2P39; light gray), which contains Cys at equivalent
position Cys66 in FGF-1 and forms a disulfide with Cys at
equivalent position Cys83.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2009,
393,
128-139)
copyright 2009.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.Lee,
and
M.Blaber
(2011).
Experimental support for the evolution of symmetric protein architecture from a simple peptide motif.
|
| |
Proc Natl Acad Sci U S A,
108,
126-130.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Lee,
S.I.Blaber,
V.K.Dubey,
and
M.Blaber
(2011).
A polypeptide "building block" for the β-trefoil fold identified by "top-down symmetric deconstruction".
|
| |
J Mol Biol,
407,
744-763.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Riazuddin,
Z.M.Ahmed,
R.S.Hegde,
S.N.Khan,
I.Nasir,
U.Shaukat,
S.Riazuddin,
J.A.Butman,
A.J.Griffith,
T.B.Friedman,
and
B.Y.Choi
(2011).
Variable expressivity of FGF3 mutations associated with deafness and LAMM syndrome.
|
| |
BMC Med Genet,
12,
21.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |